Chris Harbison
About Chris Harbison
Chris Harbison is the Executive Director of Oncology Clinical Biomarkers at Bristol Myers Squibb, with over 18 years of experience in the field and a strong background in both academic and industry research settings.
Executive Director at Bristol Myers Squibb
Chris Harbison is the Executive Director of Oncology Clinical Biomarkers at Bristol Myers Squibb, based in Princeton, New Jersey, United States. He has been with the organization since October 2005, and he brings over 18 years of experience in the field of oncology clinical biomarkers. His role is instrumental in driving the development and implementation of biomarker strategies for oncology programs.
Education and Academic Background
Chris Harbison holds a Doctor of Philosophy (Ph.D.) in Biology from the Massachusetts Institute of Technology (MIT), where he studied from 1998 to 2004. Prior to that, he completed his Bachelor of Arts (B.A.) in Biology at Harvard University, attending from 1992 to 1996. His foundational education includes studying at Christian Brothers Academy (1988-1992) and Keyport Central School.
Professional Experience in Research Institutions
Chris Harbison has a strong background in academic research, having worked at prestigious institutions. He was a Post-doctoral Associate at the Whitehead Institute from 2004 to 2005. Additionally, he served as a Research Technician at Harvard Medical School from 1996 to 1998 and as a Technician at Harvard Biology Labs for four months in 1996. These roles provided him with extensive research experience and shaped his expertise in the field of biology.
Expertise in Oncology Clinical Biomarkers
With over 18 years of experience in oncology clinical biomarkers, Chris Harbison has developed a deep understanding of the field. His expertise includes devising and implementing biomarker strategies that drive oncology programs. This extensive experience has positioned him as a key figure in his current role at Bristol Myers Squibb, where he continues to contribute significantly to the company's oncology research and development efforts.